This guidance from the ACR provides information about new remote physiologic monitoring (RPM) and remote therapeutic monitoring (RTM) treatment management codes
The ACR Urges House to Reverse NIH Research Funding Cuts
A bill approved last year by the House Appropriations Committee contains dire cuts to funding for the National Institutes of Health. The ACR is urging the House to revise this language and the Senate not to allow these cuts to go through. Contact your legislators to convey the importance of robust investment in the nation’s medical research enterprise and how funding cuts harm patient care.
Got a Private Practice Question? The Community Practice Council Can Help
ACR members in private practice on The Community Practice Council can answer questions, share experiences and offer encouragement to those interested in private practice.
UnitedHealthcare Working to Correct J Code Reimbursement Error
An error in UnitedHealthcare’s claims processing system resulted in underpayments on J code claims dated Oct. 8–Nov. 8, 2023. Practices are encouraged to review all J code payments from the final quarter of 2023.
Advancing the Work of CORC: Q&A with New Chair Chris Phillips, MD
New Committee on Rheumatologic Care (CORC) Chair Chris Phillips, MD, talks about his past work with the ACR, his experience as a private practice rheumatologist and his plans to lead CORC in addressing practitioner pain points and supporting the business side of rheumatology practice.
Pharmacokinetic Modeling & Efficacy Extrapolation: FDA Takes New Approaches to Drug Approvals
An array of new and expanded indications of therapeutics for rheumatic disease last year relied on pharmacokinetic modeling for intravenous dosing and efficacy extrapolation for pediatric populations.
Pregnancy Outcomes in Patients Treated with TNF Inhibitors
A study found the continuation of tumor necrosis factor inhibitor (TNFi) treatment in patients with chronic rheumatic inflammatory diseases after pregnancy diagnosis was not associated with worse outcomes than those who discontinued treatment with TNFi’s.
Insight into the FDA Approval of Ustekinumab Biosimilar
In late October, the FDA approved the first biosimilar to ustekinumab to treat patients with psoriasis, psoriatic arthritis and other conditions. Ustekinumab-auub is expected to be available in the U.S. by 2025.
Updates from AMA House of Delegates 2023 Interim Meeting
Last month, the ACR’s delegation to the AMA House of Delegates discussed and advanced resolutions to address specialty workforce shortages, payment reform and access to care.
Remote Prescribing Exceptions Extended Through 2024
The Department of Health & Human Services and Drug Enforcement Administration have extended through Dec. 31, 2024, exceptions that allow providers to prescribe controlled medications via telemedicine appointments without conducting an in-person evaluation.
- « Previous Page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- …
- 798
- Next Page »